Over 60% response in lung cancer tumours with rare mutation
Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations.
Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor (TKI), demonstrated a meaningful objective response rate of 66.7%, and was generally well tolerated in the Cohort 1 setting.
The results were presented in a Presidential Symposium at the IASLC 2024 World Conference on Lung Cancer (WCLC).
Paola Casarosa, Board of Managing Directors, Head of Innovation Unit at Boehringer Ingelheim, said: “Zongertinib’s efficacy and tolerability profile has the potential to become part of the future treatment landscape for patients with HER2 mutated lung tumours. Zongertinib is a perfect example of our approach to science in the discovery and development of novel treatments. Boehringer is committed to providing breakthrough therapies for cancer patients, and we look forward to advancing the zongertinib clinical programme.”
Cancer had a poor prognosis
As of May 2024, 132 patients have been treated with 120mg/240mg of zongertinib once a day. Tumour shrinkage of any magnitude was observed in 94% of all patients across doses, per investigator assessment.
The trial design includes a dose expansion that was carried out to find the optimal dose of zongertinib for this patient population. Zongertinib showed a response rate of 72.4% in patients treated with 120mg daily, and 78.2% in patients treated with 240mg daily as well as disease control rates (DCRs) of 95% and 100% respectively.
Also, 33% (120mg) and 40% (240mg) of patients with asymptomatic brain metastases achieved confirmed objective response, with a DCR of 74% and 92% respectively, as per RANO-BM (recommendations for standardised tumour response and progression assessment).
The central nervous system is a common site of metastasis in NSCLC and is associated with poor prognosis and quality of life. Brain metastases are present in up to 30% of patients with NSCLC with activating HER2 mutations at diagnosis.
“These new data could represent positive news in the future treatment of non-small cell lung cancer patients with activating HER2 mutations,” said the trial’s principal investigator, Dr John Heymach, The University of Texas MD Anderson Cancer Center. “While these mutations are rare, they are critical drivers in a subset of non-small cell lung cancer cases, and current treatment options are severely limited. Patients with this type of cancer typically face a poor prognosis, with approximately 50% responding to first-line treatment and only 20% responding to second-line therapy.”
Diana Spencer, Senior Digital Content Editor, DDW
